Tirzepatide, as an FDA-approved compound with a well-characterised safety profile, remains the more accessible and better-understood option for dual-pathway metabolic research
Most patients reach stabilization at doses between 1.0 and 2.4 mg per week (12 to 20 units), making this range evidence-backed for sustained results
The association of dietary approaches to stop hypertension (DASH) and Mediterranean diet with mental health, sleep quality and chronotype in women with overweight and obesity: a cross-sectional study
These reports likely reflect reduced oxidative burden on mitochondrial function rather than direct stimulant activity
Department of Psychiatry, University of California, San Diego, California (Schneeberger)
Lancet Diabetes Endocrinol 7(11):845854